2. Disease Areas
  3. Infection
  4. Bacterial Infection
  5. Clostridium Difficile Infection

Clostridium Difficile Infection

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated diarrhea, characterized by severe gastrointestinal symptoms including diarrhea, colitis, and potentially life-threatening complications such as toxic megacolon and sepsis. It predominantly affects hospitalized or recently antibiotic-exposed individuals, with high rates of recurrence and significant morbidity and mortality, particularly among critically ill patients. CDI poses a major challenge to healthcare systems due to its increasing incidence, complex treatment requirements, and the need for targeted interventions like antibiotics, fecal microbiota transplantation, and infection control measures.

Clostridium Difficile Infection (29):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0318
    Metronidazole 443-48-1 99.96%
    Metronidazole is an orally active nitroimidazole antibiotic. Metronidazole can cross blood brain barrier. Metronidazole can be used for the research of anaerobic infections.
    Metronidazole
  • HY-B0671
    Vancomycin 1404-90-6 99.39%
    Vancomycin is an antibiotic for the treatment of bacterial infections.
    Vancomycin
  • HY-B0113
    Omeprazole 73590-58-6 99.96%
    Omeprazole (H 16868) is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects.
    Omeprazole
  • HY-17580
    Fidaxomicin 873857-62-6 99.85%
    Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research.
    Fidaxomicin
  • HY-B0113A
    Omeprazole sodium 95510-70-6 99.10%
    Omeprazole (H 16868) sodium is an orally active H+,K+-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects.
    Omeprazole sodium
  • HY-P992123
    Ombetoxabart 3054523-85-9
    Ombetoxabart is a humanized IgG1-κ monoclonal antibody targeting TcdB (Clostridioides difficile toxin B), which exerts its function by neutralizing the toxicity of TcdB. Ombetoxabart can be used for the study of Clostridioides difficile infection.
    Ombetoxabart
  • HY-B1248
    Chlorhexidine 55-56-1 99.60%
    Chlorhexidine is a orally active cationic antimicrobial agent that targets microbial cell membranes. Chlorhexidine binds to cell membrane phospholipids non-specifically, destroys membrane structure and induces leakage of cell contents. Chlorhexidine has broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Chlorhexidine can interfere with membrane permeability, cause protein precipitation and energy metabolism disorders, such as rapid inhibition of microbial growth and induction of cell death (necrosis or apoptosis).
    Chlorhexidine
  • HY-B1092A
    Gluconate sodium 527-07-1 ≥98.0%
    Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury.
    Gluconate sodium
  • HY-B1092
    Gluconate Calcium 299-28-5 98.0%
    Gluconate (D-Gluconic acid) Calcium is an orally active glucose derivative. Gluconate Calcium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate Calcium inhibits ERK phosphorylation. Gluconate Calcium has antioxidant and antiplatelet activation activities. Gluconate Calcium has antitumor activity against colorectal cancer. Gluconate Calcium improves osteoarthritis, intestinal damage and acute lung injury.
    Gluconate Calcium
  • HY-B0608
    Chlorhexidine digluconate (20% in water) 18472-51-0 99.45%
    Chlorhexidine digluconate (20% in water) is a orally active cationic antimicrobial agent that targets microbial cell membranes. Chlorhexidine digluconate (20% in water) binds to cell membrane phospholipids non-specifically, destroys membrane structure and induces leakage of cell contents. Chlorhexidine digluconate (20% in water) has broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Chlorhexidine digluconate (20% in water) can interfere with membrane permeability, cause protein precipitation and energy metabolism disorders, such as rapid inhibition of microbial growth and induction of cell death (necrosis or apoptosis).
    Chlorhexidine digluconate (20% in water)
  • HY-P9929
    Bezlotoxumab 1246264-45-8
    Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention.
    Bezlotoxumab
  • HY-B1145
    Chlorhexidine dihydrochloride 3697-42-5 99.83%
    Chlorhexidine dihydrochloride is a orally active cationic antimicrobial agent that targets microbial cell membranes. Chlorhexidine dihydrochloride binds to cell membrane phospholipids non-specifically, destroys membrane structure and induces leakage of cell contents. Chlorhexidine dihydrochloride has broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Chlorhexidine dihydrochloride can interfere with membrane permeability, cause protein precipitation and energy metabolism disorders, such as rapid inhibition of microbial growth and induction of cell death (necrosis or apoptosis).
    Chlorhexidine dihydrochloride
  • HY-N7104
    Lactitol 585-86-4 99.96%
    Lactitol (D-Lactitol) is a non-absorbable disaccharide and Bacterial regulator. Lactitol reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol can be used in the research of portosystemic encephalopathy and chronic constipation.
    Lactitol
  • HY-105099
    Rifalazil 129791-92-0 99.64%
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).
    Rifalazil
  • HY-P99277
    Actoxumab 1245634-25-6 99.52%
    Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB.
    Actoxumab
  • HY-P99134
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
    Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis.
    Anti-Mouse GM-CSF Antibody (MP1-22E9)
  • HY-B0418AR
    Loperamide hydrochloride (Standard) 34552-83-5
    Loperamide (hydrochloride) (Standard) is the analytical standard of Loperamide (hydrochloride). This product is intended for research and analytical applications. Loperamide (hydrochloride) (R-18553 (hydrochloride)) is an opioid receptor agonist. Loperamide hydrochloride is a selective and competitive human intestinal carboxylesterases (hiCE) inhibitor. Loperamide hydrochloride has anti-diarrheal effect.
    Loperamide hydrochloride (Standard)
  • HY-W013699
    Chlorhexidine diacetate 56-95-1 99.68%
    Chlorhexidine diacetate is a orally active cationic antimicrobial agent that targets microbial cell membranes. Chlorhexidine diacetate binds to cell membrane phospholipids non-specifically, destroys membrane structure and induces leakage of cell contents. Chlorhexidine diacetate has broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Chlorhexidine diacetate can interfere with membrane permeability, cause protein precipitation and energy metabolism disorders, such as rapid inhibition of microbial growth and induction of cell death (necrosis or apoptosis).
    Chlorhexidine diacetate
  • HY-B1389
    Lactitol monohydrate 81025-04-9 98.0%
    Lactitol monohydrate (D-Lactitol monohydrate) is a non-absorbable disaccharide and Bacterial regulator. Lactitol monohydrate reduces the populations of Bacteroides, Clostridium, coliforms and Eubacterium, while increasing the populations of Lactobacillus and Streptococcus. Lactitol monohydrate can be used in the research of portosystemic encephalopathy and chronic constipation.
    Lactitol monohydrate
  • HY-17580S
    Fidaxomicin-d7 2143934-06-7
    Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora.
    Fidaxomicin-d<sub>7</sub>